Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interpace BiosciencesIDXG +2.55%41 PS Ratio is 1.23 as of Aug. 20, 2026, which is 173% above its 10-year median of 0.45. GuruFocus rates IDXG with a GF Score™ of 41/100 and a GF Value™ of $0.20 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 199 Medical Diagnostics & Research companies, Interpace Biosciences ranks better than 78.89% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Interpace Biosciences's share price is $1.61.
Interpace Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $1.30. Hence, Interpace Biosciences's PS Ratio for today is 1.23.
Warning Sign:
Interpace Biosciences Inc stock PS Ratio (=1.27) is close to 5-year high of 1.27.
The historical rank and industry rank for Interpace Biosciences's PS Ratio or its related term are showing as below:
IDXG'
s PS Ratio Range Over the Past 10 Years
Min: 0.07 Med: 0.45 Max: 2.15
Current: 1.23
During the past 13 years, Interpace Biosciences's highest PS Ratio was 2.15. The lowest was 0.07. And the median was 0.45.
IDXG's PS Ratio is ranked better than 78.89% of 199
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.81
vs IDXG: 1.23
Interpace Biosciences Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Interpace Biosciences was -83.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -42.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -28.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -25.10% per year.
During the past 13 years, Interpace Biosciences's highest 3-Year average Revenue per Share Growth Rate was 64.70% per year. The lowest was -79.20% per year. And the median was -7.40% per year.
Interpace Biosciences (OTCPK:IDXG) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Interpace Biosciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Interpace Biosciences PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's PS Ratio distribution charts can be found below:
* The bar in red indicates where Interpace Biosciences's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Interpace Biosciences's Share Price of today is $1.61. Interpace Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.30.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Interpace Biosciences (IDXG) has a PS Ratio of 1.23 as of Aug. 20, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Interpace Biosciences and its competitors. This is 173% above median its historical median of 0.45. Over the past decade, Interpace Biosciences' PS Ratio has ranged from 0.07 to 2.15. According to the industry distribution chart, Interpace Biosciences ranks #42 out of 199 companies in the Medical Diagnostics & Research industry, placing it in the top 21.1%.
Is Interpace Biosciences' PS Ratio too high?
Interpace Biosciences' current PS Ratio of 1.23 is 173% above median its 10-year median of 0.45. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 2.15. The Medical Diagnostics & Research industry median PS Ratio is 2.81. Interpace Biosciences' value of 1.23 is 56.2% below this industry median. Based on the distribution chart, Interpace Biosciences ranks #42 out of 199 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Interpace Biosciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' PS Ratio compare to PRPO and ADVB?
According to the Medical Diagnostics & Research industry distribution chart, Interpace Biosciences ranks #42 out of 199 companies for PS Ratio. This places Interpace Biosciences in the top 21% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.81. Interpace Biosciences' value of 1.23 is 56.2% below this benchmark. Historically, Interpace Biosciences' own PS Ratio has ranged from 0.07 to 2.15 over the past decade. While the company's 10-year median is 0.45 vs. the industry median of 2.81, Interpace Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.81, based on 199 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Interpace Biosciences's current PS Ratio of 1.23 is 56.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Interpace Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Interpace Biosciences's current PS Ratio is 1.23, which is 173% above median its own 10-year median of 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Interpace Biosciences (IDXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.20, compared to a current price of $1.61 — trading 705% above its estimated fair value. The current PS Ratio is 1.23, which is 173% above median its 10-year median of 0.45 and 56.2% below the Medical Diagnostics & Research industry median of 2.81. Interpace Biosciences' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Interpace Biosciences (IDXG), the current PS Ratio is 1.23 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Interpace Biosciences (IDXG) Overvalued in 2026?
Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued.
The current stock price of $1.61 is trading 705% above its estimated GF Value™ of $0.20.
GuruFocus considers Interpace Biosciences to be Significantly Overvalued.
Key valuation signals for IDXG:
PS Ratio: 1.23 (173% above median its 10-year median of 0.45)
GF Value™: $0.20 vs. price of $1.61 (705% above fair value)
Industry Position: 56.2% below the Medical Diagnostics & Research median (#42 of 199)
No single metric tells the full story. See the IDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score
Get the complete analysis for IDXG
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDXG has been successfully added to your 
